Puromycin, Dihydrochloride, Cell Culture-Tested

An aminonucleoside antibiotic that acts as a prokaryotic and eukaryotic protein synthesis inhibitor. Resembles the aminoacyl-adenylyl terminus of aminoacyl-tRNA and competes for binding to the "A site" of the large ribosomal subunit. Its incorporation into a growing polypeptide results in termination of chain elongation and release of the nascent polypeptidyl-puromycin. Useful for selection of mammalian cell lines expressing a transfected pac gene (Streptomyces alboniger), whose product puromycin acetyltransferase, inactivates the drug via acetylation. Induces DNA fragmentation in thymocytes and in human HL-60 leukemia cells. Recommended range for selection of transfected mammalian cells ranges from 1 to 30 µg/ml.

Protein synthesis inhibitor. Inhibits translation by causing premature release of nascent polypeptide chains. Induces DNA fragmentation in thymocytes and in human HL-60 leukemia cells.

Puromycin, CAS 58-58-2, is a protein synthesis inhibitor that causes premature release of nascent polypeptide chains.

Primary Target
protein synthesis

Following reconstitution, sterilize by filtration through a 0.22 µm pore-size filter, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Chow, S.C., et al. 1995. Exp. Cell Res.216, 149.
Kaufman, S.H., et al. 1993. Cancer Res.53, 3976.
de la Luna, S. and Ortín, J. 1992. Methods Enzymol.216, 376.
Chow, S.C., et al. 1991. Exp. Cell Res. 216, 149.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Harmful (C)